Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Abbott (NYSE: ABT) presented four late-breaking clinical datasets at Heart Rhythm Society 2026 showing positive outcomes for pulsed field ablation (PFA) and conduction system pacing (CSP) technologies.

Key six-month and early follow-up results: TactiFlex Duo showed 87% arrhythmia-free and 98.3% safety in 188 patients; Volt PFA reported efficient treatment (4.1 applications per vein; 10.7 per PWI) with no procedure-related complications; CSP leads (UltiSynq and AVEIR) showed high implantation success, strong safety metrics, and stable early electrical performance.

AI-generated analysis. Not financial advice.

Positive

TactiFlex Duo 87% of patients free from documented arrhythmias at six months
TactiFlex Duo 98.3% safety profile with no major safety events reported
93.3% of FlexPulse IDE patients treated exclusively with PFA
UltiSynq CSP lead 99% success meeting left bundle branch area pacing criteria
UltiSynq 100% defibrillation success with 92.5% first-shock success at 20J
Volt PFA averaged 4.1 applications per vein and 10.7 per posterior wall isolation (PWI) with no reported complications

Negative

FlexPulse IDE sample size is 188 patients—early-stage evidence with limited long-term follow-up
AVEIR leadless pacemaker data come from 19 patients with one-month follow-up only
Key devices remain investigational in the U.S., limiting immediate commercial impact

Key Figures

FlexPulse IDE sample size: 188 patients Arrhythmia-free rate: 87% Safety profile: 98.3% +5 more

8 metrics

FlexPulse IDE sample size 188 patients Six-month FlexPulse IDE study for TactiFlex Duo in complex AFib

Arrhythmia-free rate 87% Patients free from documented arrhythmias at six months in FlexPulse IDE

Safety profile 98.3% No major safety events in FlexPulse IDE six-month data

PFA-only treatments 93.3% Patients treated exclusively with PFA in FlexPulse IDE

Single ablation success 93.9% Did not require additional ablation after first therapy in FlexPulse IDE

UltiSynq safety 97.5% High safety profile with no lead-related major safety events in ASCEND CSP

LBB area pacing success 99% UltiSynq CSP meeting left bundle branch area pacing criteria

Volt PFA applications 4.1 per vein; 10.7 per PWI Average therapy applications in Volt CE Mark Extension Cohort

Market Reality Check

Price: $91.20 Vol: Volume 9,999,205 is below...

normal vol

$91.20 Last Close

Volume Volume 9,999,205 is below the 20-day average of 11,995,100, signaling muted trading interest pre‑data. normal

Technical Shares at 91.15 are trading below the 200-day MA of 121.56, reflecting a longer-term downtrend into this update.

Peers on Argus

ABT was down 1.46% while key peers were mixed: BSX -5.67%, MDT -0.23%, SYK -0.15...

ABT was down 1.46% while key peers were mixed: BSX -5.67%, MDT -0.23%, SYK -0.15%, EW +2.00%, SNN +0.38%. This points to stock-specific dynamics rather than a uniform devices move.

Common Catalyst Both Abbott and Medtronic reported clinical trial updates in electrophysiology, highlighting ongoing competition in AFib and cardiac rhythm management technologies.

Previous Clinical trial Reports

5 past events · Latest: Apr 26 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 26	Volt PFA 12-month data	Positive	+0.5%	Long-term Volt PFA study showed sustained AFib control and low complication rates.
Mar 24	IVL trial initiation	Positive	+0.7%	FDA IDE cleared for TECTONIC IVL trial in severely calcified coronary arteries.
Oct 24	Heart failure trial launch	Positive	-0.4%	TEAM-HF trial launched using CardioMEMS and HeartMate 3 for advanced HF patients.
Oct 10	PFA studies progress	Positive	-0.3%	Volt-AF IDE enrollment completed and FOCALFLEX PFA trial launched for AFib therapy.
Sep 04	DBS depression study	Positive	-0.2%	TRANSCEND pivotal DBS trial for treatment-resistant depression initiated with FDA backing.

Pattern Detected

Clinical trial news for ABT has historically produced small average moves of about 0.06%, with several instances where positive data coincided with mildly negative price reactions.

Recent Company History

Over the past year, Abbott has regularly released positive clinical data across cardiology and neuromodulation. Prior updates on the Volt™ PFA System, new AFib trials, and large studies in heart failure and depression generally showed favorable safety and efficacy signals. Market reactions were modest, with some clinical milestones followed by small share price declines. Today’s Heart Rhythm Society 2026 data extend that EP storyline by adding six‑month FlexPulse IDE results, Volt posterior wall ablation data, and early conduction system pacing outcomes.

Historical Comparison

+0.1% avg move · In the past year, Abbott released 5 clinical trial updates with an average move of just 0.06%, indic...

clinical trial

+0.1%

Average Historical Move clinical trial

In the past year, Abbott released 5 clinical trial updates with an average move of just 0.06%, indicating historically muted share reactions to pipeline data.

Clinical news has progressed from initiating major trials in heart failure, depression and intravascular lithotripsy to reporting sustained Volt™ PFA benefits and now broader pulsed field ablation and conduction system pacing results in AFib and cardiac rhythm management.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-23

Abbott has an effective Form S-3ASR shelf dated February 23, 2026, allowing it to issue various securities, including debt, common and preferred shares, depositary shares, warrants, purchase contracts, and units from time to time. The company reports 1,737,682,887 common shares outstanding versus 2,400,000,000 authorized, and has already filed 2 prospectus supplements (424B3, 424B5) under this shelf.

Market Pulse Summary

This announcement adds detailed six‑month FlexPulse IDE results, early UltiSynq and AVEIR CSP pacing...

Analysis

This announcement adds detailed six‑month FlexPulse IDE results, early UltiSynq and AVEIR CSP pacing data, and new Volt™ PFA posterior wall ablation outcomes, reinforcing Abbott’s EP portfolio. Prior clinical-trial releases produced only modest average moves of 0.06%, suggesting news-driven volatility has been limited historically. Investors may focus on durability of AFib efficacy, safety profiles, and how these technologies complement recently expanded businesses and existing cardiac franchises.

Key Terms

pulsed field ablation, conduction system pacing, implantable cardioverter-defibrillator, leadless pacemaker, +4 more

8 terms

pulsed field ablation medical

"highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel"

Pulsed field ablation is a heart procedure that uses very short, high-voltage electrical pulses to selectively disrupt abnormal heart tissue that causes irregular rhythms, rather than heating or freezing it. For investors, it matters because this approach can shorten procedure times, reduce damage to nearby structures, and potentially lower complication rates compared with traditional thermal methods, which can affect device adoption, hospital costs, and market demand for treatment tools.

conduction system pacing medical

"Two new conduction system pacing studies showcase initial results of Abbott's"

A heart-rhythm treatment where a pacemaker lead is placed to directly stimulate the heart’s natural electrical wiring so each beat follows the heart’s own pathway, producing a more natural and coordinated contraction—think of fixing a traffic signal at its source instead of directing cars from the side. It matters to investors because better outcomes and fewer complications can change demand for specific devices, shift hospital purchasing and reimbursement patterns, and influence which manufacturers and technologies gain market share.

implantable cardioverter-defibrillator medical

"UltiSynq™ CSP implantable cardioverter-defibrillator (ICD) lead and a first-in-human"

An implantable cardioverter-defibrillator (ICD) is a small electronic device placed under the skin near the chest that monitors the heartbeat and delivers a corrective electric shock or gentle pacing when it detects dangerous fast or irregular heart rhythms. Investors care because ICDs represent a durable medical-device market with upfront device sales, follow-up care and replacement procedures, and outcomes, safety records and regulatory approvals can materially affect a manufacturer’s revenue and valuation—think of it as a built-in safety device for the heart.

leadless pacemaker medical

"first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system"

A leadless pacemaker is a tiny, self-contained device implanted directly inside the heart to regulate heartbeat without the long wires used by traditional pacemakers. Think of it as a compact, wireless clock placed on the heart instead of a larger machine connected by cables. For investors it matters because the design can reduce surgical complications, shorten hospital stays, and open new markets and reimbursement pathways, affecting device makers, hospitals, and healthcare costs.

atrial fibrillation medical

"treating complex atrial fibrillation (AFib) cases with the TactiFlex™ Duo Ablation"

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

left bundle branch pacing medical

"technologies designed to deliver left bundle branch pacing (LBBP), an approach"

Left bundle branch pacing is a method of giving a heart an artificial electrical impulse by placing a pacemaker lead near the left bundle branch, a natural highway for electrical signals that make the heart beat. Like reconnecting power at a main junction instead of at individual lights, it aims to restore more natural, efficient heart timing than older pacing approaches; investors care because it can change device performance, patient outcomes, procedure demand, and reimbursement trends in the cardiac device market.

posterior wall ablation medical

"efficacy and efficiency of treatment of AFib cases for posterior wall ablationTwo"

Posterior wall ablation is a heart procedure that uses heat or cold energy to destroy small areas of tissue on the back part of the heart responsible for abnormal electrical signals, aiming to stop irregular heartbeats. For investors it matters because the procedure drives demand for specialized medical devices, training and follow-up care, and influences outcomes and complication rates that affect reimbursement, clinical adoption, and market growth for companies tied to cardiac treatments.

defibrillation medical

"100% defibrillation success, with the majority (92.5%) achieving first shock success"

Defibrillation is the delivery of a controlled electrical shock to the heart to stop dangerous, irregular rhythms and allow the heartbeat to restart a normal pattern—think of it as a jump-start for the heart. Investors care because defibrillators and related training, maintenance, and regulatory clearances are tied to sales, reimbursement, and liability exposure for medical device makers and hospitals; changes in adoption, pricing, or rules can directly affect revenues and risk for companies in this sector.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/25/2026 - 12:30 PM

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios
Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases
New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation
Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system

ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.

The data include six-month results from the FlexPulse IDE study, which examines treating complex atrial fibrillation (AFib) cases with the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, as well as new clinical evidence for posterior wall ablation with the Volt™ PFA System. Data were also presented for Abbott's ASCEND CSP IDE trial for the company's investigational UltiSynq™ CSP implantable cardioverter-defibrillator (ICD) lead, as well as a first-in-human evaluation of the LEAP2 chronic early feasibility trial for the investigational AVEIR™ CSP leadless pacemaker system.

Positive results support TactiFlex Duo Ablation Catheter, Sensor Enabled
New six-month data from the FlexPulse IDE study provide early insights showing positive patient outcomes with Abbott's TactiFlex Duo Ablation Catheter, Sensor Enabled, and confirms the strong safety and efficacy profile seen in the CE Mark study for treating complex AFib cases. The catheter provides physicians with two energy modes to tailor therapy based on a patient's complex disease or anatomy: radiofrequency – which uses heat energy that destroys tissue responsible for erratic heart signals – and PFA, which uses high energy electrical pulses that destroy the cells causing abnormal heart rhythms.

The late-breaking six-month data for the 188-patient FlexPulse IDE study show:ⁱ

The majority (87%) of patients reported being free from documented arrhythmias.
A high safety profile (98.3%) with no major safety events.
The majority (93.3%) of patients were treated exclusively with PFA, demonstrating that this energy source alone was successful in treating complex cases.
Physicians efficiently treated their patients – 93.9% did not require an additional ablation after the first round of therapy.

"The Abbott TactiFlex Duo catheter offers the convenience of seamlessly switching treatment between radiofrequency and pulsed field ablation based upon the patient's anatomy and their personalized ablation plan," said Jonathan P. Piccini, M.D., professor of medicine, Duke University Medical Center, who presented the late-breaking data at HRS. "While RF has long been a well-established ablation approach, with this study, we have been able to show that the TactiFlex Duo's point-to-point PFA is an effective approach for a significant number of our patients."

The FlexPulse IDE study was designed to secure U.S. Food and Drug Administration (FDA) approval for the TactiFlex Duo. The catheter received CE Mark in Europe earlier this year.

Promising first outcomes for Abbott's investigational conduction system pacing devices
Results from two late-breaking clinical trials evaluated Abbott's investigational leadless and traditional pacing/defibrillation CSP technologies designed to deliver left bundle branch pacing (LBBP), an approach intended to more closely replicate the heart's natural electrical activation. Both data presentations were simultaneously published in Heart Rhythm.

The ASCEND CSP IDE trial evaluated the investigational high-voltage UltiSynq CSP ICD lead designed to be implanted in the left bundle branch (LBB) area or the right ventricle to deliver both pacing and defibrillation. The three-month data show UltiSynq CSP successfully met the study's pre-specified primary safety and effectiveness endpoints. Key findings included:ⁱⁱ

A high safety profile (97.5%) with no lead-related major safety events reported.
A high success rate (99%) meeting left bundle branch area pacing (LBBAP) criteria which can be compared to results from previously reported trial(s). An 86% success rate was met using the more stringent LBBP or likely LBBP criteria. An average of fewer than one (0.9) repositioning attempt per patient was also achieved.
100% defibrillation success, with the majority (92.5%) achieving first shock success at 20J. No patients required repositioning of the ICD lead to achieve effective defibrillation.
Stable electrical performance at three months, with no inappropriate therapies delivered due to P-wave or T-wave oversensing.

"Physicians are increasingly using left bundle area pacing for pacemaker patients, because it is associated with improved physiological activation compared with traditional pacing on the right side of the heart," said Rahul N. Doshi, M.D., FHRS, FACC, professor of medicine at Arizona State University. "The data from the ASCEND trial show that an ICD lead designed for physiologic pacing can support restoration of normal heart rhythms when placed in the left bundle branch area. These early results suggest the potential to extend the benefits of physiologic pacing to ICD patients in an efficient manner."

Abbott also presented late-breaking results from a first-in-human clinical study evaluating Abbott's investigational AVEIR™ CSP leadless pacemaker system. The one-month data from the 19-patient study found a high implantation success rate along with:ⁱⁱⁱ

Delivery of pacing that closely followed the heart's natural electrical pathways.
Reliable electrical performance and functioning at the time of implant and through the first month of follow-up.
Consistent communication between devices in a dual‑chamber pacemaker setting.

New Volt PFA System data confirms freedom from AFib recurrence
Late-breaking six-month data from the Volt CE Mark Extension Cohort trial demonstrated positive outcomes for patients in which the posterior wall of the heart was treated in addition to the standard treatment.

New data from the Volt CE Mark Extension Cohort trial show:^iv

Physicians cited the device's ease of use and intuitive design as contributors to efficiently treat their patients with fewer therapy applications (4.1 applications per vein and 10.7 per PWI on average) compared to other on-market PFA systems.
A high safety profile with no reported patient or procedure-related complications.

The Volt PFA System secured FDA approval and CE Mark in Europe last year.

"Treating abnormal heart rhythms is not a siloed or one-size-fits-all approach, which is why Abbott is creating a holistic cardiovascular portfolio that empowers physicians to care for a wide range of arrhythmias," said Priya Jagasia, divisional vice president of regulatory, clinical, reimbursement and strategic initiatives at Abbott. "The data from these clinical trials serve as a cornerstone for the new innovations we're developing to help people live healthier lives."

For U.S. important safety information go to:
Volt™ PFA System
https://www.cardiovascular.abbott/us/en/ep-clinical-evidence/volt-clinical-evidence.html

TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, AVEIR™ CSP Leadless Pacemaker System, and UltiSynq™ CSP are approved for investigational use only in the U.S.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and Youtube.

_________________________

ⁱ Piccini, J. (2026, April 25). Safety and Effectiveness of a Dual-Energy Focal Ablation Catheter to Treat Paroxysmal Atrial Fibrillation: 6-Month Results of the FlexPulse IDE Study [Late Breaking Podium]. Heart Rhythm, Chicago, IL, US.

ⁱⁱSchaller, R. (2026, April 25) Safety and efficacy of a novel ICD lead for LBBAP: Results from the ASCEND CSP trial [Late Breaking Presentation]. Heart Rhythm Society 2026, Chicago IL, USA.

ⁱⁱⁱ Reddy, V. (2026, April 25) LEAP2: A first-in-human study of a chronically-implanted novel leadless pacemaker for conduction system pacing [Late Breaking Presentation]. Heart Rhythm Society 2026, Chicago IL, USA.

^iv Sanders, P. (2026, April 24). 6-Month Safety and Effectiveness of Balloon-Based PFA System Left Atrial Posterior Wall Ablation: Results from the Volt CE Mark Extension Cohort [Late Breaking Poster]. Heart Rhythm, Chicago, IL, US.

View original content:https://www.prnewswire.com/news-releases/abbott-showcases-strength-of-its-technologies-to-address-abnormal-heart-rhythms-with-late-breaking-clinical-data-at-heart-rhythm-society-2026-302753567.html

SOURCE Abbott

FAQ

What did Abbott (ABT) report about the TactiFlex Duo six-month FlexPulse IDE results on April 25, 2026?

The TactiFlex Duo showed 87% of patients free from documented arrhythmias at six months and a 98.3% safety profile. According to the company, 93.3% of patients were treated exclusively with PFA and 93.9% required no additional ablation after initial therapy.

What do the Volt PFA System CE Mark Extension Cohort results mean for ABT posterior wall ablation efficiency?

Volt PFA data showed efficient treatment with an average 4.1 applications per vein and 10.7 per PWI, and no procedure-related complications. According to the company, physicians reported ease of use and fewer therapy applications versus other on-market PFA systems.

How did Abbott's investigational UltiSynq CSP ICD lead perform in the ASCEND CSP IDE three-month readout?

UltiSynq met primary safety and effectiveness endpoints with a 97.5% safety profile and 99% LBB area pacing success. According to the company, defibrillation success was 100% with 92.5% first shock success at 20J and stable electrical performance at three months.

What were the early outcomes for Abbott's AVEIR CSP leadless pacemaker reported at HRS 2026?

The first-in-human AVEIR leadless system demonstrated high implantation success and reliable electrical performance through one month. According to the company, pacing closely followed natural conduction and devices communicated consistently in a dual-chamber setting.

Are Abbott's TactiFlex Duo, UltiSynq, AVEIR, and Volt systems U.S. approved as of April 25, 2026?

Volt PFA system has secured FDA approval, while TactiFlex Duo, AVEIR, and UltiSynq are approved for investigational use only in the U.S. According to the company, TactiFlex Duo already received CE Mark earlier in 2026.